Top Research Reports for Visa, AstraZeneca & Shell

20.05.25 22:54 Uhr

Werte in diesem Artikel
Aktien

124,30 EUR 1,85 EUR 1,51%

29,93 EUR 0,57 EUR 1,92%

325,20 EUR -2,55 EUR -0,78%

Indizes

931,1 PKT 1,5 PKT 0,16%

PKT PKT

42.677,2 PKT -114,8 PKT -0,27%

1.603,5 PKT 10,3 PKT 0,65%

8.781,1 PKT 81,8 PKT 0,94%

4.764,6 PKT 42,6 PKT 0,90%

19.142,7 PKT -72,8 PKT -0,38%

3.519,6 PKT -17,6 PKT -0,50%

8.209,0 PKT 24,7 PKT 0,30%

2.431,8 PKT 37,0 PKT 1,54%

2.563,1 PKT 14,2 PKT 0,56%

973,1 PKT 3,4 PKT 0,35%

2.883,5 PKT -11,6 PKT -0,40%

5.940,5 PKT -23,1 PKT -0,39%

4.581,6 PKT 27,5 PKT 0,60%

Tuesday, May 20, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AstraZeneca PLC (AZN) and Shell plc (SHEL), as well as two micro-cap stocks Ocean Power Technologies, Inc. (OPTT) and Wheeler Real Estate Investment Trust, Inc. (WHLR).  The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.You can see all of today’s research reports here >>> Ahead of Wall StreetThe daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.You can read today's AWS here >>> Pre-Markets Flat After "V-Shaped Rally" Off April LowsToday's Featured Research ReportsVisa’s shares have outperformed the Zacks Financial Transaction Services industry over the past year (+38.7% vs. +27.5%). The company’s strategic acquisitions and alliances are fostering long-term growth and consistently driving revenues. The company expects net revenues to grow in high-single to low-double digits in fiscal 2025. Visa, fueled by persistent increases in payments, cross-border volumes and sustained investments in technology, is witnessing significant profit growth. The ongoing shift to digital payments is advantageous for Visa, with strong domestic volumes supporting its overall performance. A robust cash position enables the company to enhance shareholder value. However, Visa’s elevated operating expenses pose margin challenges. We expect adjusted operating expenses to rise 9.5% year over year in fiscal 2025. The company is witnessing a volatile cash volume from the Asia Pacific and U.S. regions. Hence, the stock warrants a cautious stance.(You can read the full research report on Visa here >>>)Shares of AstraZeneca have outperformed the Zacks Medical - Biomedical and Genetics industry over the year-to-date period (+9% vs. -5%). The company beat Q1 estimates for earnings but missed on sales. Its key drugs like Lynparza, Tagrisso, Imfinzi, and Fasenra should keep driving revenues. AstraZeneca’s pipeline is strong, with pivotal late and mid-stage pipeline data readouts lined up. It has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets. Backed by its new products and pipeline drugs, AstraZeneca believes it can post industry-leading top-line growth in the 2025-2030 period. However, potentially lower sales of Lynparza and Farxiga in China, the impact of Part D redesign on U.S. oncology sales and slowing sales of rare disease drugs are expected to hurt the top line in 2025. (You can read the full research report on AstraZeneca here >>>)Shell’s shares have outperformed the Zacks Oil and Gas - Integrated - International industry over the year-to-date period (+8% vs. -1.3%). The company, being the largest oil firm in Europe, has solid fundamentals, and the stock looks fairly balanced at the moment. London-based Shell plc remains a global leader in liquefied natural gas (LNG). Shell leverages its strong LNG position, bolstered by the acquisition of BG Group, to generate consistent earnings by capitalizing on steady demand for this transitional fuel. Strategic moves like the Equinor JV and Pavilion Energy acquisition also support long-term growth. However, a few red flags keep the outlook in check: Q1 revenue missed by $10B, chemical margins remain weak, and reserve replacement continues to lag. Add macro risks, delayed earnings impact from new projects, and ongoing pressure from the energy transition, and the near-term setup feels mixed. For now, investors may prefer to wait for a better entry point before buying Shell shares.(You can read the full research report on Shell here >>>)Shares of Ocean Power Technologies have outperformed the Zacks Alternative Energy - Other industry over the past year (+202.3% vs. +42.5%). This microcap company with market capitalization of $90.50 million offers strong revenue visibility with a record $7.5 million backlog, driven by global demand for its AI-enabled PowerBuoy and WAM-V platforms across defense and commercial sectors. Financial discipline is evident as cash burn fell 41% and liquidity rose to $10.2 million. Ocean Power Technologies shift to a recurring revenue model (DaaS/RaaS) enhances margin potential and customer stickiness. Advanced autonomous systems support long-duration maritime ops with minimal oversight, addressing needs in defense, energy, and environmental monitoring. However, risks include persistent losses ($15.1 million YTD), liquidity concerns, high client concentration, and dilution from equity financing. Products remain in early commercialization, and governance issues plus emerging market exposure introduce further uncertainty. OPTT's growth potential is clear, but execution and financial sustainability remain critical watchpoints.(You can read the full research report on Ocean Power Technologies here >>>)Wheeler Real Estate Investment’s shares have underperformed the Zacks REIT and Equity Trust - Retail industry over the past year (-99.9% vs. +11.4%). This microcap company with market capitalization of $3.32 million have equity value is pressured by dilution from preferred redemptions and stock splits, and liquidity has tightened, with $489 million in debt and a decline in cash to $19.2 million. Legal overhang, weakening NOI, and declining Cedar leasing trends signal operational headwinds. Despite a high implied Series D dividend yield, risks from asset erosion, derivative liabilities and regional concentration constrain long-term upside. Despite ongoing challenges, WHLR’s valuations offer a potential value opportunity relative to its historical norms and industry peers.Nevertheless, Wheeler Real Estate has improved its balance sheet via $13 million in Series D Preferred redemptions and $18.3 million in asset sales, reducing leverage and generating $5.7 million in net gains. Occupancy remains strong at 93.3%, with leasing spreads reinforcing pricing power.(You can read the full research report on Wheeler Real Estate Investment here >>>)Other noteworthy reports we are featuring today include Deere & Company (DE), Roper Technologies, Inc. (ROP) and United Rentals, Inc. (URI).Director of ResearchSheraz Mian Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>Today's Must ReadVisa (V) Rides On Cross Border Volume Growth, Expenses HighKey Drugs Aid AstraZeneca (AZN) Sales, Pipeline StrongShell (SHEL) to Benefit from LNG Demand GrowthFeatured ReportsDeere (DE) Gains from Pricing Efforts Amid Low DemandPer the Zacks analyst, low commodity prices will hurt demand for Deere's agricultural equipment in the coming quarters. However, this will be offset by its pricing actions and cost-reduction efforts. Application Software unit Aids Roper (ROP) Amid Rising CostsPer the Zacks analyst, Roper's Application Software unit is driven by solid momentum across the Deltek, Vertafore, PowerPlan and Aderant businesses. However, High operating costs remain a concern.Solid end Markets Aid United Rentals (URI), High Costs AilPer the Zacks analyst, United Rentals benefits from strong demand in construction and industrial end markets. However, high costs and the cyclical nature of business are major concerns.Iron Mountain (IRM) Gains From Data Center & Storage DemandPer the Zacks Analyst, Iron Mountain is set to gain from healthy revenue management and volume trends in the storage business and focus on data centers. Strategic buyouts supplement organic growth.Warner Bros. Discovery (WBD) Rides on Strong DTC BusinessPer the Zacks analyst, Warner Bros. Discovery's streaming service Max is growing rapidly, targeting 150 million subscribers by 2026.Bio-Techne's (TECH) Growth Verticals Expand Amid Fund IssuesThe Zacks analyst is impressed with Bio-Techne's strong growth across its core growth verticals like Cell and Gene, and Diagnostics. Yet, a challenging funding environment in biotech is concerning.Interparfums' (IPAR) Sales Gain on Solid Brand PerformancePer the Zacks analyst, Interparfums' sales are benefiting from solid brand growth, which continued in the first quarter of 2025. Net sales of $339 million rose 5% year over year in the quarter.New UpgradesBill Holdings (BILL) Rides on Strong SMB Business clientelePer the Zacks analyst, Bill is benefiting from an expanding small and medium business clientele, as well as a diversified business model.BlackBerry (BB) Banks on QNX Strength, Cost-Saving EffortsPer the Zacks analyst, increasing design wins in the core digital cockpit and ADAS of QNX business is boosting BlackBerry's performance. Cost-cutting and restructuring measures augur well.Market Expansion and Low Debt Benefits Green Dot (GDOT)Per the Zacks analyst, banking-as-a-service account programs are aiding Green Dot to expand its market reach. Low debt allows cash for growth initiatives.New DowngradesTariff Imposed on Other Countries are Likely to Hurt First Solar(FSLR)Per the Zacks analyst, First Solar is likely to lose from reciprocal tariff imposed on nearly all U.S. trading partners, including Vietnam, India and Malaysia.Oil Price Volatility & High Costs Ail Cenovus Energy (CVE)Per the Zacks analyst, high turnaround expenses and maintenance activities might impact Cenovus Energy's near-term profitability. Declining oil prices may also put pressure on upstream revenues.Workday (WDAY) Plagued by Stiff Competition, Legal ChallengesPer the Zacks analyst, recent legal issues due to allegations that Workday AI tools exhibit bias will likely hinder prospects. Fierce competition with Oracle and SAP remains a headwind.5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2024. While not all picks can be winners, previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis Report Visa Inc. (V): Free Stock Analysis Report Deere & Company (DE): Free Stock Analysis Report Roper Technologies, Inc. (ROP): Free Stock Analysis Report Ocean Power Technologies, Inc. (OPTT): Free Stock Analysis Report United Rentals, Inc. (URI): Free Stock Analysis Report Wheeler Real Estate Investment Trust, Inc. (WHLR): Free Stock Analysis Report Shell PLC Unsponsored ADR (SHEL): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Visa und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf AstraZeneca

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf AstraZeneca

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Shell (ex Royal Dutch Shell)

Wer­bung

Analysen zu Shell (ex Royal Dutch Shell)

DatumRatingAnalyst
19.05.2025Shell (ex Royal Dutch Shell) BuyJefferies & Company Inc.
08.05.2025Shell (ex Royal Dutch Shell) BuyGoldman Sachs Group Inc.
07.05.2025Shell (ex Royal Dutch Shell) OverweightJP Morgan Chase & Co.
07.05.2025Shell (ex Royal Dutch Shell) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.05.2025Shell (ex Royal Dutch Shell) BuyGoldman Sachs Group Inc.
DatumRatingAnalyst
19.05.2025Shell (ex Royal Dutch Shell) BuyJefferies & Company Inc.
08.05.2025Shell (ex Royal Dutch Shell) BuyGoldman Sachs Group Inc.
07.05.2025Shell (ex Royal Dutch Shell) OverweightJP Morgan Chase & Co.
07.05.2025Shell (ex Royal Dutch Shell) BuyJoh. Berenberg, Gossler & Co. KG (Berenberg Bank)
07.05.2025Shell (ex Royal Dutch Shell) BuyGoldman Sachs Group Inc.
DatumRatingAnalyst
26.08.2020Shell (Royal Dutch Shell) (A) UnderweightBarclays Capital
29.11.2017Shell B SellCitigroup Corp.
29.11.2017Shell (Royal Dutch Shell) (A) SellCitigroup Corp.
29.11.2017Shell B SellCitigroup Corp.
30.01.2015Royal Dutch Shell Grou b SellS&P Capital IQ

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Shell (ex Royal Dutch Shell) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen